Sassine leaves Visiomed
07 February, 2005 by Renate KrelleWA biotech Visiomed (ASX:VSG) has replaced retiring CEO Saliba Sassine with William Dolphin, formerly of New Zealand's SpectraNet and patient monitoring equipment company, SonaMed.
Peptech reaffirms acquisition strategy
07 February, 2005 by Renate KrellePeptech (ASX:PTD) CEO Mel Bridges used today's annual general meeting to reveal that the company is keen to use its AUD$65 million warchest to fund acquisitions.
In brief: ResMed, Meditech, Ventracor
04 February, 2005 by Staff WritersResMed (ASX:RMD) shares were up almost 5 per cent today after the company announced record revenue and income results for the quarter ended December 31 Revenue for the quarter was US$103.9 million, a 26 per cent increase over the same quarter last year. Net income for the quarter was US$17.4 million.
Biotech's in for a good year, says Burrill
04 February, 2005 by Renate KrelleThe Burrill Biotech Select Index slipped 4.6 per cent in January, but Steve Burrill is bullish about 2005, despite the ramifications of the Merck-Vioxx situation spilling over into the biotech sector.
Western Australian GM ban becomes election issue
03 February, 2005 by Graeme O'NeillWestern Australia's moratorium on genetically modified crops has emerged as a potential electoral liability for state premier Geoff Gallop's ALP government, as the state approaches a cliffhanger election.
Progen aims for first-line therapy
02 February, 2005 by Graeme O'NeillBrisbane cancer-drug developer Progen Industries (ASX:PGL, NASDAQ:PGLAF) is planning a new trial of its lead compound PI-88 in patients with metastatic melanoma - this time as an adjuvant therapy to prevent the deadly cancer progressing in newly diagnosed patients.
Norwood Immunology gets IND for bone marrow therapy
02 February, 2005 by Graeme O'NeillMelbourne immune therapy developer Norwood Immunology Ltd (AIM:NIM) has announced that the US Food and Drug Administration has granted investigational new drug (IND) approval for its first bone-marrow transplant trial in cancer patients
Starpharma and Anadis to develop biodefence antibodies
01 February, 2005 by Graeme O'NeillMelbourne biotechs Starpharma (ASX:SPL, USOTC:SPHRY) and Anadis are teaming up to develop a two-pronged defence against biowarfare agents like pneumonic plague and anthrax.
Judge lays out timetable for Biota-GSK stoush
01 February, 2005 by Melissa TrudingerThe timetable for the legal fight between Biota (ASX: BTA) and pharmaceutical giant GlaxoSmithKline (GSK) has been agreed to by the companies' legal teams.
Acrux pushes forward
01 February, 2005 by Melissa TrudingerIn the four months since it listed on the ASX, Melbourne-based Acrux (ASX: ACR) has had a busy time of it. This week the company announced successful completion of its Phase I study for a transdermal spray to deliver pain drug Fentanyl to treat severe chronic pain. CEO Igor Gonda is confident that this outcome gives the company an attractive commercial opportunity.
Ferriscan receives FDA approval
28 January, 2005 by Melissa TrudingerInner Vision Biometrics (IVB), a subsidiary of Perth based Resonance Health (ASX: RHT) has received FDA marketing approval for its novel diagnostic test for liver iron concentrations.
Starpharma, DNT nab Dow dendrimer patents
27 January, 2005 by Melissa TrudingerStarpharma shares (ASX:SPL) have surged more than 8.5 per cent on heavy trading after details of the company's three way deal with Dow Chemical and Dendritic NanoTechnologies (DNT) were finally revealed this morning.
Fiona Wood, C3 co-founder, named Australian of the Year
27 January, 2005 by Graeme O'NeillPlastic surgeon Prof Fiona Wood, co-founder of Perth-based biotech Clinical Cell Culture (ASX:CCE), has been honoured for her role in developing a living spray-on skin to treat burns victims by being named the 2005 Australian of the Year.
Heartware closes oversubscribed
27 January, 2005 by Renate KrelleUS artificial heart firm Heartware expects to have a market capitalisation of AUD$76.42 million when it lists on the ASX on Monday, having raised US$24.95 million (AUD$32.42 million) in an oversubscribed initial public offering.
Biopharm firms scoop US VC pool
27 January, 2005 by Renate KrelleInvestment in biopharmaceutical companies by US venture capitalists increased by 20 per cent in 2004 over the previous year, a new report has shown.
